Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study
Amirian, E. Susan , Zhou, Renke, Wrensch, Margaret , Olson, Sara H. , Scheurer, Michael E. , Armstrong, Georgina , McCoy, Lucie , Lau, Ching C., Claus, Elizabeth B. , Barnholtz‐Sloan, Jill S. , Schildkraut, Joellen M. , Ali‐Osman, Francis, Sadetzki, Siegal , Johansen, Christoffer , Houlston, Richard S. , Jenkins, Robert B. , Bernstein, Jonine L. , Merrell, Ryan , Davis, Faith G., Lai, Rose , Shete, Sanjay , Melin, Beatrice , Bondy, Melissa L. , Lachance, Daniel, Il’yasova, Dora , Lachance, Daniel Honore , Armstrong, Georgina , Amos, Christopher I. , Houlston, Richard S , Barnholtz-Sloan, Jill S

Cancer Epidemiology, Biomarkers & Prevention | February 5, 2016 | Volume: 25 | Issue: 2 | Pages: 282-290

10.1158/1055-9965.epi-15-0847 | PMID 26908595 Get It

Abstract Background: Several previous studies have found inverse associations between glioma susceptibility and a history of allergies or other atopic conditions. Some evidence indicates that respiratory allergies are likely to be particularly relevant with regard to glioma risk. Using data from the Glioma International Case-Control Study (GICC), we examined the effects of respiratory allergies and other atopic conditions on glioma risk. Methods: The GICC contains detailed information on history of atopic conditions for 4,533 cases and 4,171 controls, recruited from 14 study sites across five countries. Using two-stage random-effects restricted maximum likelihood modeling to calculate meta-analysis ORs, we examined the associations between glioma and allergy status, respiratory allergy status, asthma, and eczema. Results: Having a history of respiratory allergies was associated with an approximately 30% lower glioma risk, compared with not having respiratory allergies (mOR, 0.72; 95% confidence interval, 0.58–0.90). This association was similar when restricting to high-grade glioma cases. Asthma and eczema were also significantly protective against glioma. Conclusion: A substantial amount of data on the inverse association between atopic conditions and glioma has accumulated, and findings from the GICC study further strengthen the existing evidence that the relationship between atopy and glioma is unlikely to be coincidental. Impact: As the literature approaches a consensus on the impact of allergies in glioma risk, future research can begin to shift focus to what the underlying biologic mechanism behind this association may be, which could, in turn, yield new opportunities for immunotherapy or cancer prevention. Cancer Epidemiol Biomarkers Prev; 25(2); 282–90. ©2016 AACR.
Tools of the Trade: Point-of-Care Ultrasonography as a Stethoscope
Sekiguchi, Hiroshi

Seminars in Respiratory and Critical Care Medicine | February 4, 2016 | Volume: 37 | Issue: 01 | Pages: 068-087

10.1055/s-0035-1570353 | PMID 26844609 Get It

Socioeconomic gradients between locally transplanted and exported liver donors and recipients
Adler, Joel T. , Hyder, Joseph A. , Markmann, James F. , Axelrod, David A. , Yeh, Heidi , Axelrod, David

Liver Transplantation | February 4, 2016 | Volume: 22 | Issue: 4 | Pages: 557-558

10.1002/lt.24410 | PMID 26845498 Get It

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Hoff, Daniel D. Von , Mita, Monica , Ramanathan, Ramesh K., Mita, Alain C. , LoRusso, Patricia , Burris, Howard A. , Hart, Lowell L., Low, Susan C. , Parsons, Donald M., Zale, Stephen E., Summa, Jason M., Youssoufian, Hagop , Sachdev, Jasgit C. , Weiss, Glen J.

Clinical Cancer Research | February 4, 2016 | Volume: 22 | Issue: 13 | Pages: 3157-3163

10.1158/1078-0432.ccr-15-2548 | PMID 26847057 Get It

Abstract Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)–targeted nanoparticle, containing docetaxel. Experimental Design: Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m2 and 15 to 45 mg/m2, respectively. Results: BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non–small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. Conclusions: BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly. Clin Cancer Res; 22(13); 3157–63. ©2016 AACR.
Experimental testing of the dual-layer Woven EndoBridge device using an elastase-induced aneurysm model in rabbits
Ding, Yong-Hong, Schroeder, Dana , Kadirvel, Ramanathan , Kallmes, David F. , Dai, Daying , Ding, Yonghong

Interventional Neuroradiology | February 4, 2016 | Volume: 22 | Issue: 3 | Pages: 299-303

10.1177/1591019916628202 | PMID 26847799 Get It

The dual-layer Woven EndoBridge (WEB) device (WEB II) is designed to improve the performance of the first-generation WEB device. This study was performed to evaluate the acute and chronic performance of WEB II for aneurysm occlusion in an elastase-induced aneurysm model in rabbits. We implanted WEB II devices in 36 elastase-induced aneurysms and followed up for one, three, six, and 12 months. Degree of aneurysm occlusion at follow-up was graded on the Web Occlusion Scale (WOS): Grade A, complete aneurysm occlusion; Grade B, complete occlusion with recess filling; Grade C, residual neck filling; and Grade D, residual aneurysm filling. Hematoxylin and eosin staining was performed for histological assessment of aneurysm healing. Grades A, B, C, and D aneurysm occlusion at one-month follow-up were noted in three (17%), three (17%), eight (44%), and four (22%) of 18 cases, respectively. At the three-month time point Grades A, B, C, and D were shown in two (33%), two (33%), one (17%), and one (17%) aneurysms. Six months after treatment, one (17%), two (33%), two (33%), and one (17%) cases demonstrated Grades A, B, C, and D occlusion. At the 12-month time point, Grades B, C, and D were shown in three (50%), two (33%), and one (17%) aneurysms. Histologic evaluation showed progressive thrombus organization within aneurysm lumen from one to 12 months. These results indicated that the WEB II device can achieve high rates of aneurysm occlusion over time in experimental aneurysms.
The use of pembrolizumab for the treatment of metastatic uveal melanoma
Kottschade, Lisa A. , Block, Matthew S. , Pham, Anthony , Esplin, Brandt L., Dronca, Roxana , McWilliams, Robert R. , Markovic, Svetomir N. , Villasboas, José C.

Melanoma Research | February 4, 2016 | Volume: 26 | Issue: 3 | Pages: 300-303

10.1097/cmr.0000000000000242 | PMID 26848796 Get It

Uveal melanoma is a rare type of melanoma, with only five to seven cases per one million persons diagnosed each year. Patients with metastatic melanoma of uveal origin tend to have lower response rates on traditional therapies. Herein we report our experience with 10 patients with metastatic uveal melanoma (MUM) who received pembrolizumab. Eligible patients were more than or equal to 18 years old, had unresectable MUM, progressed on prior ipilimumab therapy, had good performance status (Eastern Cooperative Oncology Group of 0 or 1), and adequate organ and marrow function. Patients could have central nervous system disease, but needed to be clinically stable. Patients were treated with 2 mg/kg pembrolizumab intravenously over 30 min every 3 weeks until disease progression, unacceptable toxicity, or for up to 2 years. Between April 2014 and October 2014, we treated a total of 10 patients with MUM with pembrolizumab. Median age was 65 years, with 70% being female. As of the data cutoff date of 14 May 2015, median progression-free survival was 18 weeks (range 3.14–49.3 weeks), with four patients still currently receiving therapy. Of eight evaluable patients, there was one complete response, two partial responses, and one patient with stable disease. Four patients had rapidly progressive disease. Toxicities were as expected and were usually grade 1/2 in nature. Although this cohort of patients was small, to our knowledge this is the first such report of outcomes in uveal melanoma patients being treated with anti-PD1 therapy. In the absence of a clinical trial, treatment with pembrolizumab appears to be a viable option for patients with MUM.
Author response: Targeting senescent cells enhances adipogenesis and metabolic function in old age
Ding, Husheng, Weivoda, Megan , Pirtskhalava, Tamar , White, Thomas A. , Sepe, Anna, Johnson, Kurt O. , Giorgadze, Nino, Jensen, Michael D. , Kirkland, James L. , Xu, Ming , Palmer, Allyson K. , Stout, Michael B , LeBrasseur, Nathan K. , Tchkonia, Tamar

No container title available | February 4, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.12997.028 Get It

Clinical delineation of the PACS1‐related syndrome—Report on 19 patients
Schuurs-Hoeijmakers, Janneke , Landsverk, Megan , Foulds, Nicola , Kukolich, Mary K. , Gavrilova, Ralitza H. , Greville‐Heygate, Stephanie , Hanson‐Kahn, Andrea , Bernstein, Jonathan A. , Glass, Jennifer, Burrow, Thomas Andrew, Husami, Ammar , Collins, Kathleen , Wusik, Katie, Aa, Nathalie Van der, Kooy, R. Frank , Brown, Kate Tatton, Gadzicki, Dorothea, Kini, Usha , McGehee, Frank T., Selby, Katherine, Tarailo‐Graovac, Maja , Allen, Margot Van, Stavropoulos, Dimitri J. , Marshall, Christian R. , Merico, Daniele , Gregor, Anne , Zweier, Christiane , Chu, Yoyo W. Y., Vries, Bert B.A. de , Brunner, Han G. , study, DDD, Chitayat, David A. , Collins, Kathleen , Álvarez, Sara , Fernández‐Jaén, Alberto , Allen, Margot I. Van, Karnebeek, Clara van , Hopkin, Robert J. , Chung, Hon-Yin B , Devriendt, Koenraad , Hurles, Matthew E. , study, DDD, Kooy, Frank , de Vries, Bert B A , Marshall, Christian R.

American Journal of Medical Genetics Part A | February 4, 2016 | Volume: 170 | Issue: 3 | Pages: 670-675

10.1002/ajmg.a.37476 | PMID 26842493 Get It

We report on 19 individuals with a recurrent de novo c.607C>T mutation in PACS1. This specific mutation gives rise to a recognizable intellectual disability syndrome. There is a distinctive facial appearance (19/19), characterized by full and arched eyebrows, hypertelorism with downslanting palpebral fissures, long eye lashes, ptosis, low set and simple ears, bulbous nasal tip, wide mouth with downturned corners and a thin upper lip with an unusual “wavy” profile, flat philtrum, and diastema of the teeth. Intellectual disability, ranging from mild to moderate, was present in all. Hypotonia is common in infancy (8/19). Seizures are frequent (12/19) and respond well to anticonvulsive medication. Structural malformations are common, including heart (10/19), brain (12/16), eye (10/19), kidney (3/19), and cryptorchidism (6/12 males). Feeding dysfunction is presenting in infancy with failure to thrive (5/19), gastroesophageal reflux (6/19), and gastrostomy tube placement (4/19). There is persistence of oral motor dysfunction. We provide suggestions for clinical work‐up and management and hope that the present study will facilitate clinical recognition of further cases. © 2016 Wiley Periodicals, Inc.
Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis
Parikh, Sameer A. , Strati, Paolo , Tsang, Mazie , West, Colin P. , Shanafelt, Tait D.

Blood | February 4, 2016 | Volume: 127 | Issue: 14 | Pages: 1752-1760

10.1182/blood-2015-10-620864 | PMID 26841802 Get It

AbstractSince the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binet staging systems described ∼40 years ago have proven to be robust prognostic tools. Over the past 2 decades, several novel biological, genetic, and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems. In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL. The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so. In addition to clinical stage, these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL. This approach will allow the application of powerful, recently developed prognostic indices (all of which are dependent on IGHV and FISH results) to all patients with newly diagnosed CLL.